Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study.

被引：1
|
作者：
Di Giacomo, Anna Maria
Covre, Alessia
Finotello, Francesca
Rieder, Dietmar
Sigalotti, Luca
Giannarelli, Diana
Petitprez, Florent
Lacroix, Laetitia
Cutaia, Ornella
Fazio, Carolina
Coral, Sandra
Anichini, Andrea
Bock, Christoph
Lowder, James N.
Azab, Mohammad
Fridman, Wolf-Herman
Sautes-Fridman, Catherine
Trajanoski, Zlatko
Maio, Michele
机构：
[1] Univ Hosp Siena, Med Oncol & Immunotherapy, Siena, Italy
[2] Univ Hosp Siena, Ctr Immunooncol, Siena, Italy
[3] Med Univ Innsbruck, Bioctr, Div Bioinformat, Innsbruck, Austria
[4] Ctr Riferimento Oncol CRO Aviano, Oncogenet & Funct Oncogen Unit, Aviano, Italy
[5] Regina Elena Inst Canc Res, IRCSS, Rome, Italy
[6] Cordeliers Res Ctr, INSERM, UMR S 1138, Paris, France
[7] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[8] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria
[9] Astex Pharmaceut, Dublin, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.2549
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2549
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: The NIBIT-M4 study.
    Di Giacomo, Anna Maria
    Covre, Alessia
    Taverna, Pietro
    Coral, Sandra
    Amato, Giovanni
    Keer, Harold N.
    Lowder, James N.
    Giannarelli, Diana
    Azab, Mohammad
    Maio, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial
    Di Giacomo, Anna Maria
    Covre, Alessia
    Finotello, Francesca
    Rieder, Dietmar
    Danielli, Riccardo
    Sigalotti, Luca
    Giannarelli, Diana
    Petitprez, Florent
    Lacroix, Laetitia
    Valente, Monica
    Cutaia, Ornella
    Fazio, Carolina
    Amato, Giovanni
    Lazzeri, Andrea
    Monterisi, Santa
    Miracco, Clelia
    Coral, Sandra
    Anichini, Andrea
    Bock, Christoph
    Nemc, Amelie
    Oganesian, Aram
    Lowder, James
    Azab, Mohammad
    Fridman, Wolf H.
    Sautes-Fridman, Catherine
    Trajanoski, Zlatko
    Maio, Michele
    CLINICAL CANCER RESEARCH, 2019, 25 (24) : 7351 - 7362
  • [3] A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: The NIBIT-M4 Study
    Maio, M.
    Covre, A.
    Coral, S.
    Amato, G.
    Taverna, P.
    Lowder, J.
    Azab, M.
    Giannarelli, D.
    Natali, P. G.
    Di Giacomo, A. M.
    ANNALS OF ONCOLOGY, 2015, 26 : 7 - 7
  • [4] A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma - the NIBIT-M1 Trial
    Di Giacomo, A. M.
    Ascierto, P. A.
    Pittiglio, E.
    Queirolo, P.
    Pilla, L.
    Ridolfi, R.
    Santinami, M.
    Testori, A.
    Parmiani, G.
    Maio, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S653 - S654
  • [5] Guadecitabine plus ipilimumab in unresectable melanoma: Five-year follow-up and correlation with integrated, multi-omic analysis in the NIBIT-M4 trial
    Noviello, Teresa
    Di Giacomo, Anna Maria
    Caruso, Francesca Pia
    Covre, Alessia
    Scala, Giovanni
    Ferraro, Luigi
    Coral, Sandra
    Fridman, Wolf H.
    Sautes-Fridman, Catherine
    Mortarini, Roberta
    Simonetti, Elena
    Lofiego, Maria Fortunata
    Bedognetti, Davide
    Anichini, Andrea
    Ceccarelli, Michele
    Maio, Michele
    CANCER RESEARCH, 2023, 83 (07)
  • [6] Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial
    Teresa Maria Rosaria Noviello
    Anna Maria Di Giacomo
    Francesca Pia Caruso
    Alessia Covre
    Roberta Mortarini
    Giovanni Scala
    Maria Claudia Costa
    Sandra Coral
    Wolf H. Fridman
    Catherine Sautès-Fridman
    Silvia Brich
    Giancarlo Pruneri
    Elena Simonetti
    Maria Fortunata Lofiego
    Rossella Tufano
    Davide Bedognetti
    Andrea Anichini
    Michele Maio
    Michele Ceccarelli
    Nature Communications, 14 (1)
  • [7] Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial
    Noviello, Teresa Maria Rosaria
    Di Giacomo, Anna Maria
    Caruso, Francesca Pia
    Covre, Alessia
    Mortarini, Roberta
    Scala, Giovanni
    Costa, Maria Claudia
    Coral, Sandra
    Fridman, Wolf H.
    Sautes-Fridman, Catherine
    Brich, Silvia
    Pruneri, Giancarlo
    Simonetti, Elena
    Lofiego, Maria Fortunata
    Tufano, Rossella
    Bedognetti, Davide
    Anichini, Andrea
    Maio, Michele
    Ceccarelli, Michele
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [8] A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: The NIBIT-M1 trial.
    Di Giacomo, A. M.
    Ascierto, P. A.
    Fonsatti, E.
    Pittiglio, E.
    Queirolo, P.
    Pilla, L.
    Ridolfi, R.
    Santinami, M.
    Testori, A.
    Parmiani, G.
    Maio, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases
    Maio, Michele
    Testori, Alessandro
    Ascierto, Paolo Antonio
    Ridolfi, Ruggero
    Santinami, Mario
    Pilla, Lorenzo
    Queirolo, Paola
    Grosso, Marco
    Simeone, Ester
    Vittoria, Stefania
    Nicoletti, Luisa
    Rivoltini, Licia
    Ferrucci, Pier Francesco
    Parmiani, Giorgio
    Di Giacomo, Anna Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial.
    Di Giacomo, Anna Maria
    Annesi, Diego
    Ascierto, Paolo Antonio
    Calabro, Luana
    Chiarion-Sileni, Vanna
    Danielli, Riccardo
    Del Vecchio, Michele
    Ferraresi, Virginia
    Ferrucci, Pier Francesco
    Fonsatti, Ester
    Guida, Michele
    Giannarelli, Diana
    Guidoboni, Massimo
    Mandala, Mario
    Quaglino, Pietro
    Queirolo, Paola
    Maccalli, Cristina
    Parmiani, Giorgio
    Maio, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345